CRP and myocardial infarction: CANTOS was a multicenter, randomized, double-blind, placebo-controlled trial of 10,061 patients with a previous myocardial infarction, inflammatory atherosclerosis, and a persistent proinflammatory response—defined as a high-sensitivity CRP (hs-CRP) level over 2 mg/L.